The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Systemic Sjögrens: More Than a Sicca Disease

Systemic Sjögrens: More Than a Sicca Disease

November 1, 2014 • By Pilar Brito-Zerón, MD, PhD, and Manuel Ramos-Casals, MD, PhD, on behalf of the EULAR-SS Task Force Group

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The two internal organs that have the greatest influence on the survival of patients with pSS are the lungs and the kidneys. SS-related pulmonary disease is clearly associated with worsened quality of life and poorer survival, with a two- to four-fold increase in the risk of death compared with patients without pulmonary disease.3 With respect to renal involvement, a recent study, including 35 patients with biopsy-proven renal involvement, found high rates of adverse outcomes, including chronic renal failure (31%), lymphoma (26%) and death (26%), especially in patients with cryoglobulinemic glomerulonephitis.3,10

You Might Also Like
  • Insights into Celiac Disease & Systemic Autoimmune Diseases
  • Atherosclerosis, Cardiovascular Disease More Common in Patients with Primary Sjögren’s Syndrome
  • Causes of Alopecia Can Vary Among Patients with Systemic Disease Say Experts at the 2013 ACR/ARHP Annual Meeting
Explore This Issue
November 2014

IgG4-Related Disease, the Great Mimicker

Some systemic diseases may mimic the clinical picture of systemic Sjögren’s through tissue infiltration by granulomas (i.e., sarcoidosis), amyloid proteins (i.e., amyloidosis) or malignant cells (i.e., hematologic neoplasia). However, a new disease was recently added to infiltrative diseases that may mimic systemic Sjögren’s. IgG4-related disease (IgG4-RD) is a systemic immune-mediated disease that has been previously described in Japan and is characterized by tissue infiltration of IgG4-bearing plasma cells.11 It is not a new disease, because many previously recognized conditions of unknown etiology and pathogenesis formerly regarded as entirely disparate disorders are now considered to comprise parts of the IgG4-RD spectrum, including Mikulicz disease, Küttner’s tumor and Riedel thyroiditis, among others.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Major salivary glands are among the organs more frequently involved in the IgG4-related disease, reported in 40% of cases.12 Involvement of internal organs is common and may lead to organ failure or severe systemic impairment, particularly in the pancreas, liver and biliary tree, kidneys, thyroid gland, lungs and aorta. A significant number of these organ-specific involvements are common with pSS, including renal, pulmonary, hepatic, thyroid and central nervous system disease (see Figure 2). A specific evaluation for IgG4 disease should be considered for patients with pSS who present with pancreatic signs, renal disease or interstitial pulmonary involvement.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Organ-specific involvement in IgG4-related disease in comparison with systemic Sjögren’s.
Figure 2: Organ-specific involvement in IgG4-related disease in comparison with systemic Sjögren’s.

Systemic Therapies: Targeting B Cells

Systemic therapy should be tailored to the organ involved and the severity of the condition, although no controlled trials in pSS guide their use.13 For patients with moderate systemic involvement, including arthritis, non-complicated cutaneous purpura or non-severe peripheral neuropathy, prednisone (<0.5 mg/kg/d) may suffice. For patients with internal organ involvement (e.g., pulmonary alveolitis, glomerulonephritis or severe neurologic features), the traditional therapeutic approach consists of a combination of prednisone and immunosuppressive agents (e.g., cyclophosphamide, azathioprine or mycophenolate), especially in patients with associated vasculitic involvement. However, some extraglandular features, such as interstitial nephritis, axonal polyneuropathy or ataxic neuronopathy, seem to have a poor response to corticosteroids and immunosuppressive agents.14

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis, SLE (Lupus), Soft Tissue Pain Tagged With: Brito-Zerón, EULAR-SS Task Force Group, Fibromyalgia, IgG4 related disease, Ramos-Casals, Rheumatoid arthritis, sicca, Sjögren's syndrome, Systemic lupus erythematosusIssue: November 2014

You Might Also Like:
  • Insights into Celiac Disease & Systemic Autoimmune Diseases
  • Atherosclerosis, Cardiovascular Disease More Common in Patients with Primary Sjögren’s Syndrome
  • Causes of Alopecia Can Vary Among Patients with Systemic Disease Say Experts at the 2013 ACR/ARHP Annual Meeting
  • Researchers Look for Therapeutic Clues to Sjögrens Syndrome in Neural Pathways

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.